[1]梁海红.细胞学诊断在浆膜腔积液中的应用现状[J].医学信息,2020,33(13):30-34.[doi:10.3969/j.issn.1006-1959.2020.13.009]
 LIANG Hai-hong.Application Status of Cytological Diagnosis in Serous Cavity Effusion[J].Medical Information,2020,33(13):30-34.[doi:10.3969/j.issn.1006-1959.2020.13.009]
点击复制

细胞学诊断在浆膜腔积液中的应用现状()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年13期
页码:
30-34
栏目:
综述
出版日期:
2020-07-01

文章信息/Info

Title:
Application Status of Cytological Diagnosis in Serous Cavity Effusion
文章编号:
1006-1959(2020)13-0030-05
作者:
梁海红
(天津港口医院病理科,天津 300456)
Author(s):
LIANG Hai-hong
(Department of Pathology,Tianjin Port Hospital,Tianjin 300456)
关键词:
浆膜腔积液肿瘤标志物免疫细胞化学DNA倍体
Keywords:
Serous cavity effusionTumor markersImmunocytochemistryDNA ploidy
分类号:
R446.8
DOI:
10.3969/j.issn.1006-1959.2020.13.009
文献标志码:
A
摘要:
细胞学检查是诊断浆膜腔积液的重要手段,不仅可以评估疾病的良恶性,还可以用于判断肿瘤的类型、来源、预后等方面的信息。本文主要从制片技术、肿瘤标志物检测、DNA倍体分析、免疫组化和分子病理在浆膜腔积液中的应用进行综述,旨在为浆膜腔积液的临床诊治提供参考。
Abstract:
Cytological examination is an important method for diagnosing serous cavity effusion. It can not only evaluate the benign and malignant diseases, but also be used to judge the type, source, and prognosis of tumors. This article mainly reviews the application of preparation technology, tumor marker detection, DNA ploidy analysis, immunohistochemistry and molecular pathology in serous cavity effusion, aiming to provide reference for clinical diagnosis and treatment of serous cavity effusion.

参考文献/References:

[1]陈肖霞.探讨如何制作优质胸腹水涂片[J].医学信息,2015,28(21):337.[2]王全志,丁伟,田少华.浆膜腔脱落细胞学制片方法质量控制的对比研究[J].诊断病理学杂志,2015,22(1):60-62.[3]禹乐,孟加榕,朱启淦,等.液基薄层细胞涂片在胸腹水诊断中的应用价值[J].山西医科大学学报,2017,48(2):149-152.[4]Faria SC,Sagebiel T,Patnana M,et al.Tumor markers:myths and facts unfolded[J].Abdominal Radiology,2018(44):1575-1600.[5]张盟,王宗兰,杨东昌,等.肿瘤标志物检测在良恶性胸腹水鉴别价值研究[J].国际免疫学杂志,2015,38(4):340-342.[6]Pasaoglu G,Zamani A,Can G,et al.Diagnostic Value Of CEA,CA19-9,CA125 And CA15-3 Levels In Malignant Pleural Fluids[J].European Journal of General Medicine,2015,4(4):165-171.[7]Tozzoli R,Basso SM,D’Aurizio F,et al.Evaluation of predictive value of pleural CEA in patients with pleural effusions and histological findings:A prospective study and literature review[J].Clin biochem,2016,49(16-17):1227-1231.[8]Zhai K,Wang W,Wang Y,et al.Diagnostic accuracy of tumor markers for malignant pleural effusion:a derivation and validation study[J].J Thorac Dis,2017,9(12):5220-5229.[9]Kanaji N,Kadota K,Tadokoro A,et al.Serum CYFRA 21-1 but not Vimentin is Associated with Poor Prognosis in Advanced Lung Cancer Patients[J].Open Respir Med J,2019(13):31-37.[10]Gu Y,Qiao X,Wang L,et al.The diagnostic value of parallel detection of cytokeratin 19 fragment-based tumor markers in malignant pleural effusion:a systematic review and metaanalysis[J].Biomedical Research,2017,28(18):8105-8114.[11]Feng M,Zhu J,Liang L,et al.Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion:a validation study and meta-analysis[J].Int J Clin Oncol,2017,22(2):283-290.[12]Trapé J,Gurt G,Franquesa J,et al.Diagnostic Accuracy of Tumor Markers CYFRA21-1 and CA125 in the Differential Diagnosis of Ascites[J].Anticancer research,2015,35(10):5655-5660.[13]Sica GL,Choi IH,Zhu G,et al.B7-H4,a molecule of the B7 family,negatively regulates T cell immunity[J].Immunity.2003,18(6):849-861.[14]Jing X,Wei F,Li J,et al.Diagnostic value of soluble B7-H4 and carcinoembryonic antigen in distinguishing malignant from benign pleural effusion[J].Clin Respir J,2018,12(3):986-990.[15]Chen M,Xie S,Wan C,et al.Diagnostic performance of CTLA-4,carcinoembryonic antigen and CYFRA 21-1 for malignant pleural effusion[J].Postgrad Med,2017,129(6):644-648.[16]Kim BC,Bae JH,Park SM,et al.Is ascites CEA a risk factor for peritoneal carcinomatosis in colorectal cancer:a long-term follow-up study[J].Int J Colorectal Dis,2020,35(1):147-155.[17]Li J,Liu L,Feng Z,et al.Tumor markers CA15-3,CA125,CEA and breast cancer survival by molecular subtype:a cohort study[J].Breast Cancer,2020,27(4):621-630.[18]Gordon DJ,Resio B,Pellman D.Causes and consequences of aneuploidy in cancer[J].Nat Rev Genet,2012,13(3):189-203.[19]王应霞,张旋,吴莹莹,等.液基细胞学检测联合DNA倍体分析在良恶性胸腹水鉴别诊断中的应用[J].临床与实验病理学杂志,2016,32(10):1152-1155.[20]胡艳芬,陈龙,荆超,等.流式细胞术检测DNA倍体数对鉴别良恶性肿瘤价值的Meta分析[J].中国医科大学学报,2015,(2):136-142.[21]何秋阳,钟国梁,杨国顺,等.DNA倍体分析与细胞学检测对良恶性浆膜腔积液诊断的比较[J].实验与检验医学,2018,36(3):317-319.[22]He Z,Li Y,Wang W.Combination of flow cytometry and image cytometry for detecting DNA aneuploidy and improving the diagnostic efficiency of effusion(Article)[J].Anal Quant Cytopathol Histpathol,2018,40(2):85-90.[23]孙小蓉,汪键.DNA定量细胞学[M].武汉:湖北科学技术出版社,2011:135-148.[24]AGJM Hanselaar.Additional techniques in serous effusions[J].Anal Cell Pathol,2002,24(1):1-4.[25]Meng Z,Shi J,Zhu C,et al.Automated quantification of DNA aneuploidy by image cytometry as an adjunct for the cytologic diagnosis of malignant effusion[J].Anal Cell Pathol(Amst),2013,36(3-4):107-115.[26]解建军,敖腾巴雅尔,张永欢.可疑恶性浆膜腔积液细胞块中免疫组织化学抗体的应用[J].中华病理学杂志,2018,47(11):858-860.[27]赵银环,杜芸,王珩,等.细胞HE涂片褪色后行免疫细胞化学的改良技术[J].临床与实验病理学杂志,2016,32(1):106-107.[28]赵乐.细胞学胸腹水腺癌与间皮细胞的鉴别诊断[J].辽宁医学杂志,2019(5):12-14.[29]Ranade RS,Reddy P,Giriyan SS.Cytological Diagnosis Of Serous Effusion By Comparative Approach Of Routine Staining And Modified Cell Block Technique[J].J Evid Based Med,2018,5(3):229-232.[30]Güldaval F,Anar C,Polat G,et al.Contribution of Cell Block Obtained by Thoracentesis in the Diagnosis of Malignant Pleural Effusion[J].J Cytol,2019,36(4):205-208.[31]Woo CG,Son SM,Han HS,et al.Diagnostic benefits of the combined use of liquid-based cytology,cell block,and carcinoembryonic antigen immunocytochemistry in malignant pleural effusion[J].J Thorac Dis,2018,10(8):4931-4939.[32]林梅英,李伟,王伟源.免疫组化染色在肺腺癌胸水涂片褪色后的应用研究[J].临床肺科杂志,2018,23(3):410-412.[33]马晓燕,王敏,李静,等.肺癌胸水多种制片法与免疫细胞化学的联合应用[J].诊断病理学杂志,2018,25(11):770-775.[34]Li W,Zhang Z,Guo L,et al.Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer[J].Oncotarget,2016,7(7):8332-8340.[35]Nakamichi S,Seike M,Miyanaga A,et al.RT-PCR for detecting ALK translocations in cytology samples from lung cancer patients[J].Anticancer Res,2017,37(6):3295-3299.[36]中国非小细胞肺癌ALK检测模式真实世界多中心研究专家组,中华医学会病理学分会分子病理学组.中国非小细胞肺癌ALK检测临床实践专家共识[J].中华病理学杂志,2019,48(12):913-920.[37]Gornjec A,Novakovic S,Stegel V,et al.Cytology material is equivalent to tumor tissue in determining mutations of BRCA1/2 genes in patients with tubo-ovarian high grade serous carcinoma[J].BMC Cancer,2019,19(1):296-396.

相似文献/References:

[1]钟 磊,谢海燕,林 霖.电化学发光免疫分析技术检测肿瘤标志物在乳腺癌诊断中的应用[J].医学信息,2018,31(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
 ZHONG Lei,XIE Hai-yan,LIN Lin.Application of Electrochemiluminescence Immunoassay for Detection of Tumor Markers in Diagnosis of Breast Cancer[J].Medical Information,2018,31(13):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
[2]兰福全,李秀云,卢 斌.四种肿瘤标志物对肝癌诊断的临床意义[J].医学信息,2018,31(21):164.[doi:10.3969/j.issn.1006-1959.2018.21.048]
 LAN Fu-quan,LI Xiu-yun,LU Bin.The Clinical Significance of Four Tumor Markers in the Diagnosis of Liver Cancer[J].Medical Information,2018,31(13):164.[doi:10.3969/j.issn.1006-1959.2018.21.048]
[3]魏优蕾,郭晓彤.肺癌患者血浆检测肿瘤标志物的分析方法及展望[J].医学信息,2019,32(07):39.[doi:10.3969/j.issn.1006-1959.2019.07.014]
 WEI You-lei,GUO Xiao-Tong.Analytical Methods and Prospects of Plasma Detection of Tumor Markers in Patients with Lung Cancer[J].Medical Information,2019,32(13):39.[doi:10.3969/j.issn.1006-1959.2019.07.014]
[4]杨寿林,宋庆志,吴路发,等.肿瘤标志物和凝血指标在肺癌辅助诊断中的效果分析[J].医学信息,2019,32(07):168.[doi:10.3969/j.issn.1006-1959.2019.07.053]
 YANG Shou-lin,SONG Qing-zhi,WU Lu-fa,et al.Efficacy Analysis of Tumor Markers and Coagulation Parameters in the Diagnosis of Lung Cancer[J].Medical Information,2019,32(13):168.[doi:10.3969/j.issn.1006-1959.2019.07.053]
[5]张东霞.腹腔镜下卵巢子宫内膜样囊肿剥除术对患者肿瘤标志物及卵巢储备功能的影响[J].医学信息,2022,35(13):116.[doi:10.3969/j.issn.1006-1959.2022.13.026]
 ZHANG Dong-xia.Effect of Laparoscopic Ovarian Endometrioid Cystectomy on Tumor Markers and Ovarian Reserve Function[J].Medical Information,2022,35(13):116.[doi:10.3969/j.issn.1006-1959.2022.13.026]
[6]曹 冬.腹腔镜治疗肠癌的效果及对血清CEA水平的影响[J].医学信息,2022,35(16):86.[doi:10.3969/j.issn.1006-1959.2022.16.020]
 CAO Dong.The Effect of Laparoscopic Treatment of Colorectal Cancer and its Effect on Serum CEA Level[J].Medical Information,2022,35(13):86.[doi:10.3969/j.issn.1006-1959.2022.16.020]
[7]杨丽娴.槐耳颗粒联合艾立布林治疗晚期三阴性乳腺癌的真实世界研究[J].医学信息,2023,36(19):144.[doi:10.3969/j.issn.1006-1959.2023.19.032]
 YANG Li-xian.A Real-world Study of Huai’er Granules Combined with Eribulin in the Treatment of Advanced Triple-negative Breast Cancer[J].Medical Information,2023,36(13):144.[doi:10.3969/j.issn.1006-1959.2023.19.032]
[8]杨天敬,李 然,苏卫东.CA153、CA125联合HER-2检测在乳腺癌各临床分期诊断中的应用[J].医学信息,2020,33(07):173.[doi:10.3969/j.issn.1006-1959.2020.07.058]
 YANG Tian-jing,LI Ran,SU Wei-dong.Application of CA153 and CA125 Combined with HER-2 Detection in the Diagnosis of Breast Cancer in Different Clinical Stages[J].Medical Information,2020,33(13):173.[doi:10.3969/j.issn.1006-1959.2020.07.058]
[9]刘瀚予,贾莉莉,喻文立,等.外泌体在肝癌中的作用机制研究进展[J].医学信息,2020,33(08):26.[doi:10.3969/j.issn.1006-1959.2020.08.010]
 LIU Han-yu,JIA Li-li,YU Wen-li,et al.The Mechanism of Exosomes in Liver Cancer[J].Medical Information,2020,33(13):26.[doi:10.3969/j.issn.1006-1959.2020.08.010]
[10]侯晓杰.免疫治疗药物对非小细胞肺癌的有效性和安全性研究[J].医学信息,2022,35(18):118.[doi:10.3969/j.issn.1006-1959.2022.18.032]
 HOU Xiao-jie.Study on the Efficacy and Safety of Immunotherapy Drugs for Non-small Cell Lung Cancer[J].Medical Information,2022,35(13):118.[doi:10.3969/j.issn.1006-1959.2022.18.032]

更新日期/Last Update: 1900-01-01